2245085-41-8Relevant articles and documents
HETEROTRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
-
Page/Page column 47;49; 50, (2022/02/24)
The present invention relates to a heterotricyclic compound as shown in formula (I), and a preparation method therefor and use thereof. The compound is an SHP2 inhibitor. The present invention also relates to a pharmaceutical composition comprising the compound as an active ingredient. The pharmaceutical composition can be used for treating and/or preventing diseases associated with abnormal SHP2 protein activity.
Salt of nitrogen-containing heteroaromatic derivative and crystal form thereof
-
, (2021/10/13)
The invention relates to a salt of a nitrogen-containing heteroaromatic derivative and a crystal form thereof. The invention specifically relates to a salt with a general formula (I) and a crystal form thereof. A preparation method and a pharmaceutical composition containing the salt of the derivative and a crystal form thereof, as a protein tyrosine phosphatase - 2C (SHP2) inhibitor, and application thereof to treatment of diseases or diseases such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer.
PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF
-
, (2021/10/07)
The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen hetero
SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF
-
, (2021/12/30)
Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.
Compound serving as SHP2 inhibitor and application thereof
-
Paragraph 0103; 0114-0116; 0340; 0350-0352, (2021/05/12)
The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.
REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF
-
Paragraph 0109; 0575; 0588-0590, (2021/08/27)
The present invention relates to a regulator of nitrogen-containing heteroaromatic derivatives, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer, wherein the definition of each substituent in the general formula (I) is the same as that in the description.
SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF
-
Page/Page column 45; 46, (2021/11/06)
Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.
PROTEIN TYROSINE PHOSPHATASE INHIBITORS
-
, (2020/10/20)
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Pyrazinothiazole compound and application thereof, and pharmaceutical composition containing pyrazinothiazole compound
-
Paragraph 0087-0088; 0100-0103, (2020/11/09)
The invention discloses a pyrazinothiazole compound, an application of the pyrazinothiazole compound, and a pharmaceutical composition containing the pyrazinothiazole compound, and provides a pyrazinothiazole compound represented by a formula A or a pharmaceutically acceptable salt of the pyrazinothiazole compound. The pyrazinothiazole compound provided by the invention has relatively good SHP2 inhibitory activity.
SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF
-
Paragraph 0161-0163, (2020/10/20)
Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.